Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Cancer Immunotherapy
This volume details multiple areas of new and emerging methods to develop the next generation of immunotherapy treatments. Chapters guide readers through analysis and characterisation of the interactions between tumour and immune cells, and cell engineering tools for cancer treatment, to provide a unique and compelling set of techniques instrumental to work with, and engineer, immune cells. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Cancer Immunotherapy: Methods and Protocols aims to ensure successful results in the further study of this vital field.
Emerging Learnings in Cell Therapy: Novel Binding Domains, Universal CAR-T Cells, and More
The Past decade has seen significant advances in cancer immunotherapy with the development of multiple strategies including monoclonal antibodies targeting checkpoint blockers, oncolytic viruses, fusion proteins and cell therapies such as tumor-specific chimeric antigen receptor (CAR-) T cell therapy, NK cell therapy and γδ-T-cell therapy. Multiple cell therapies including sipuleucel-T (Provange), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have been approved by the US FDA for different hematological cancers and hormone-refractory prostate cancer (Provange). Impressive results were noted with CAR-T cell therapy with objective response rates (ORR) as high as 100% in certain hematological cancers and with responses durable over 10 years in some patients.
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
Dr. Koguchi receives funding from Tesaro, a GSK company, Bristol-Myers Squibb, and Shimadzu Corporation.. Dr. Vujanovic is a co-inventor of a methodology licensed to INmune Bio, Inc. where a selective inhibitor of soluble TNF can be used to prevent or treat malignancies. Dr. Hansen is the recipient of a private grant from Eurostars Eureka. The other Topic Editors declare no competing interests.
AACR 2022 Proceedings: Part A Online-Only and April 10
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
Johnny Depp
None
